Eva Guinan

Publications

1. Allostimulation leads to emergence of a human B cell population with increased expression of HLA class I antigen presentation-associated molecules and the immunoglobulin receptor FcRL5. Am J Transplant. 2024 Nov; 24(11):1968-1978. View Abstract
2. Health professionals' perceptions of prehabilitation before haematopoietic cell transplantation to optimise candidacy in older adults. Support Care Cancer. 2024 Jun 26; 32(7):465. View Abstract
3. Retention rates and reasons for non-retention in exercise oncology trials in the post-treatment phase-a systematic review. J Cancer Surviv. 2024 Apr 03. View Abstract
4. Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial. Am J Transplant. 2023 12; 23(12):1872-1881. View Abstract
5. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. Transplant Cell Ther. 2023 02; 29(2):125.e1-125.e9. View Abstract
6. Physical Therapists in Oncology Settings: Experiences in Delivering Cancer Rehabilitation Services, Barriers to Care, and Service Development Needs. Phys Ther. 2022 03 01; 102(3). View Abstract
7. Conservatism Gets Funded? A Field Experiment on the Role of Negative Information in Novel Project Evaluation. Manage Sci. 2022 Jun; 68(6):4478-4495. View Abstract
8. Ex vivo generation of regulatory T cells from liver transplant recipients using costimulation blockade. Am J Transplant. 2022 02; 22(2):504-518. View Abstract
9. Engineering serendipity: When does knowledge sharing lead to knowledge production? Strateg Manag J. 2021 Jun; 42(6):1215-1244. View Abstract
10. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020 05 23; 395(10237):1627-1639. View Abstract
11. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries. Biol Blood Marrow Transplant. 2020 02; 26(2):333-342. View Abstract
12. Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 12; 25(12):2398-2407. View Abstract
13. Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting. JAMA Oncol. 2019 May 01; 5(5):654-661. View Abstract
14. Alloanergization Method for Inducing Allospecific Hyporesponsiveness in PBMC Exposed to Allostimulation In Vitro in the Context of Costimulatory Molecule Blockade. Methods Mol Biol. 2019; 1899:103-118. View Abstract
15. Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. Pediatr Blood Cancer. 2019 01; 66(1):e27460. View Abstract
16. Toward a more scientific science. Science. 2018 09 21; 361(6408):1194-1197. View Abstract
17. The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data. NPJ Schizophr. 2018 Jun 27; 4(1):14. View Abstract
18. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018 09 01; 24(17):4098-4109. View Abstract
19. rBPI21 (Opebacan) Promotes Rapid Trilineage Hematopoietic Recovery in a Murine Model of High-Dose Total Body Irradiation. Am J Hematol. 2018 May 11. View Abstract
20. Amelioration of Head and Neck Radiation-Induced Mucositis and Distant Marrow Suppression in Fanca-/- and Fancg-/- Mice by Intraoral Administration of GS-Nitroxide (JP4-039). Radiat Res. 2018 06; 189(6):560-578. View Abstract
21. The views of patients with metastatic prostate cancer towards physical activity: a qualitative exploration. Support Care Cancer. 2018 Jun; 26(6):1747-1754. View Abstract
22. A Field Experiment on Search Costs and the Formation of Scientific Collaborations. Rev Econ Stat. 2017 10; 99(4):565-576. View Abstract
23. Physical activity and advanced cancer: the views of oncology and palliative care physicians in Ireland. Ir J Med Sci. 2018 May; 187(2):337-342. View Abstract
24. Stepwise Distributed Open Innovation Contests for Software Development: Acceleration of Genome-Wide Association Analysis. Gigascience. 2017 05 01; 6(5):1-10. View Abstract
25. Three sides to a story: Child, parent, and nurse perspectives on the child's experience during hematopoietic stem cell transplantation. Cancer. 2017 Aug 15; 123(16):3159-3166. View Abstract
26. Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. Blood. 2017 04 20; 129(16):2308-2315. View Abstract
27. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. Bone Marrow Transplant. 2017 Feb; 52(2):270-278. View Abstract
28. Ex Vivo Costimulatory Blockade to Generate Regulatory T Cells From Patients Awaiting Kidney Transplantation. Am J Transplant. 2016 07; 16(7):2187-95. View Abstract
29. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65. View Abstract
30. Intraoral Mitochondrial-Targeted GS-Nitroxide, JP4-039, Radioprotects Normal Tissue in Tumor-Bearing Radiosensitive Fancd2(-/-) (C57BL/6) Mice. Radiat Res. 2016 Feb; 185(2):134-50. View Abstract
31. Looking Across and Looking Beyond the Knowledge Frontier: Intellectual Distance, Novelty, and Resource Allocation in Science. Manage Sci. 2016 Oct; 62(10):2765-2783. View Abstract
32. Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation. F1000Res. 2015; 4:1480. View Abstract
33. Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. Nat Genet. 2015 Dec; 47(12):1482-8. View Abstract
34. Parent Outlook: How Parents View the Road Ahead as They Embark on Hematopoietic Stem Cell Transplantation for Their Child. Biol Blood Marrow Transplant. 2016 Jan; 22(1):104-11. View Abstract
35. The impact of pediatric blood and marrow transplant on parents: introduction of the parent impact scale. Health Qual Life Outcomes. 2015 Apr 09; 13:46. View Abstract
36. Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation. Pediatr Blood Cancer. 2015 Apr; 62(4):687-92. View Abstract
37. Changing factors associated with parent activation after pediatric hematopoietic stem cell transplant. Support Care Cancer. 2015 Jul; 23(7):1997-2006. View Abstract
38. Aplastic anemia in adolescents and young adults. Acta Haematol. 2014; 132(3-4):331-9. View Abstract
39. Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children. J Pediatr Gastroenterol Nutr. 2014 Jun; 58(6):709-14. View Abstract
40. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014 Sep; 134(3):560-567.e4. View Abstract
41. Calculating the costs of an 8-week, physiotherapy-led exercise intervention in deconditioned cancer survivors in the early survivorship period (the PEACH trial). Physiotherapy. 2014 Jun; 100(2):182-4. View Abstract
42. Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells. Am J Transplant. 2014 Feb; 14(2):305-18. View Abstract
43. Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin. Innate Immun. 2014 Oct; 20(7):697-711. View Abstract
44. Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: the PEACH trial. J Cancer Surviv. 2013 Dec; 7(4):551-62. View Abstract
45. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol. 2013 May 01; 31(13):1669-76. View Abstract
46. Experiments in Open Innovation at Harvard Medical School: What happens when an elite academic institution starts to rethink how research gets done? MIT Sloan Manag Rev. 2013; 54(3):45-52. View Abstract
47. The effect of aerobic exercise on metabolic and inflammatory markers in breast cancer survivors--a pilot study. Support Care Cancer. 2013 Jul; 21(7):1983-92. View Abstract
48. Prize-based contests can provide solutions to computational biology problems. Nat Biotechnol. 2013 Feb; 31(2):108-11. View Abstract
49. A young adult with aplastic anemia and gray hair. Clin Chem. 2013 Jan; 59(1):47-50. View Abstract
50. Effect of weight on outcomes of children undergoing hematopoietic cell transplantation. Pediatr Hematol Oncol. 2013 Mar; 30(2):116-30. View Abstract
51. Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. J Pediatric Infect Dis Soc. 2012 Jun; 1(2):103-11. View Abstract
52. Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant. 2012; 21(9):2047-61. View Abstract
53. Attenuation of resting energy expenditure following hematopoietic SCT in children. Bone Marrow Transplant. 2012 Oct; 47(10):1301-6. View Abstract
54. Effect of titrated parenteral nutrition on body composition after allogeneic hematopoietic stem cell transplantation in children: a double-blind, randomized, multicenter trial. Am J Clin Nutr. 2012 Feb; 95(2):342-51. View Abstract
55. Factors associated with parental activation in pediatric hematopoietic stem cell transplant. Med Care Res Rev. 2012 Apr; 69(2):194-214. View Abstract
56. Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med. 2011 Nov 23; 3(110):110ra118. View Abstract
57. Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. Biochem Soc Trans. 2011 Aug; 39(4):994-9. View Abstract
58. 17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol. 2011 Sep; 90(3):459-70. View Abstract
59. Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease. Br J Haematol. 2011 Jul; 154(2):278-81. View Abstract
60. Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. J Vis Exp. 2011 Mar 14; (49). View Abstract
61. Outcome of hematopoietic stem cell transplant in children with congenital heart disease. Pediatr Transplant. 2011 Feb; 15(1):75-80. View Abstract
62. Diagnosis and management of aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:76-81. View Abstract
63. Therapy for aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011; 2011:82-3. View Abstract
64. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 2010 May 15; 70(10):3915-24. View Abstract
65. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17. View Abstract
66. A multi-center, randomized, controlled trial of parenteral nutrition titrated to resting energy expenditure in children undergoing hematopoietic stem cell transplantation ("PNTREE"): rationale and design. Contemp Clin Trials. 2010 Mar; 31(2):157-64. View Abstract
67. Preservation of immune repertoire by selective depletion of haploidentical grafts. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S68-74. View Abstract
68. Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med. 2009 Oct 07; 1(1):1ra3. View Abstract
69. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68. View Abstract
70. Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am. 2009 Apr; 23(2):171-91. View Abstract
71. Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity. Transplantation. 2008 Sep 27; 86(6):854-64. View Abstract
72. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood. 2008 Nov 15; 112(10):4318-27. View Abstract
73. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood. 2008 Sep 15; 112(6):2232-41. View Abstract
74. Weekly measurements accurately represent trends in resting energy expenditure in children undergoing hematopoietic stem cell transplantation. JPEN J Parenter Enteral Nutr. 2008 Jul-Aug; 32(4):427-32. View Abstract
75. Prognostic factors in the resumption of oral dietary intake after allogeneic hematopoietic stem cell transplantation (HSCT) in children. JPEN J Parenter Enteral Nutr. 2007 Jul-Aug; 31(4):295-301. View Abstract
76. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol. 2007 Feb; 136(4):549-64. View Abstract
77. Antigen-specific T-lymphocyte function after cord blood transplantation. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1335-42. View Abstract
78. A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma. Pediatr Transplant. 2006 Sep; 10(6):669-76. View Abstract
79. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):919-27. View Abstract
80. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant. 2006 Jan; 37(1):73-80. View Abstract
81. Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Sep; 11(9):721-31. View Abstract
82. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005 Sep 01; 106(5):1749-54. View Abstract
83. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94. View Abstract
84. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22. View Abstract
85. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005 Mar; 11(3):261-2. View Abstract
86. Aplastic anemia: management of pediatric patients. Hematology Am Soc Hematol Educ Program. 2005; 104-9. View Abstract
87. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol. 2005 Jan; 128(2):221-3. View Abstract
88. Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. Bone Marrow Transplant. 2004 Nov; 34(9):795-8. View Abstract
89. Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol. 2004 Nov; 127(3):322-5. View Abstract
90. Dyskeratosis congenita vs. chronic graft versus host disease: report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Nov; 98(5):566-71. View Abstract
91. A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2004 Sep; 10(9):635-44. View Abstract
92. Endotoxemia and elevation of lipopolysaccharide-binding protein after hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2003 Nov; 22(11):978-81. View Abstract
93. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003 Dec 15; 102(13):4567-75. View Abstract
94. Homozygous alpha-thalassemia treated with intrauterine transfusions and postnatal hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003 Aug; 32(3):341-2. View Abstract
95. Changes in resting energy expenditure among children undergoing allogeneic stem cell transplantation. Am J Clin Nutr. 2003 Jul; 78(1):104-9. View Abstract
96. Waiting for organ transplantation: results of an analysis by an Institute of Medicine Committee. Biostatistics. 2003 Apr; 4(2):207-22. View Abstract
97. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15; 75(3):389-97. View Abstract
98. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6. View Abstract
99. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43. View Abstract
100. Neutrophil defense in patients undergoing bone marrow transplantation: bactericidal/permeability-increasing protein (BPI) and defensins in graft-derived neutrophils. Transplantation. 2002 May 15; 73(9):1522-6. View Abstract
101. Marrow failure. Hematology Am Soc Hematol Educ Program. 2002; 58-72. View Abstract
102. Impact of pharmacy practices on the cost of colony-stimulating factor use in pediatric stem cell transplantation: an institution-based analysis. J Pediatr Hematol Oncol. 2001 Jan; 23(1):19-24. View Abstract
103. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. 2001; 106(1-2):57-68. View Abstract
104. Balancing efficacy with cost: antiemetic control in the pediatric stem cell transplant (SCT) population. Bone Marrow Transplant. 2000 Mar; 25(5):553-7. View Abstract
105. The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol. 1999 Dec; 107(3):485-93. View Abstract
106. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999 Jun 03; 340(22):1704-14. View Abstract
107. Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired marrow failure syndromes. Br J Haematol. 1998 Nov; 103(2):304-7. View Abstract
108. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant. 1998 Oct; 22(8):735-41. View Abstract
109. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. View Abstract
110. Subtyping analysis of Fanconi anemia by immunoblotting and retroviral gene transfer. Mol Med. 1998 Jul; 4(7):468-79. View Abstract
111. Clinical aspects of aplastic anemia. Hematol Oncol Clin North Am. 1997 Dec; 11(6):1025-44. View Abstract
112. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997 Nov; 20(9):737-43. View Abstract
113. Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med. 1997 Sep; 42(9):537-41. View Abstract
114. Tacrolimus (FK506) in allogeneic bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation. Bone Marrow Transplant. 1997 Aug; 20(3):257-60. View Abstract
115. Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 1997 Jul; 20(1):33-8. View Abstract
116. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106. View Abstract
117. Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 1997 Apr; 19(2):169-74. View Abstract
118. Isolated testicular relapse in an adolescent 5 years following allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant. 1997 Apr; 19(8):849-51. View Abstract
119. Bone marrow transplantation in sickle cell anemia--the dilemma of choice. N Engl J Med. 1996 Aug 08; 335(6):426-8. View Abstract
120. Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1149-55. View Abstract
121. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996 Jun 01; 87(11):4887-93. View Abstract
122. Long-term follow-up of 12 pediatric patients with primary myelodysplastic syndrome treated with HLA-identical sibling donor bone marrow transplantation. Blood. 1996 May 01; 87(9):4020-2. View Abstract
123. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996 Apr 01; 87(7):3012-8. View Abstract
124. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore). 1996 Mar; 75(2):77-8. View Abstract
125. GM-CSF clinical trials: pediatric aplastic anemia and Fanconi's anemia. Pediatr Nurs. 1995 Jul-Aug; 21(4):345-9. View Abstract
126. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15; 84(10):3261-82. View Abstract
127. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994 Aug 15; 84(4):1342-8. View Abstract
128. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994 Mar 15; 57(5):677-84. View Abstract
129. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr. 1994 Jan; 124(1):144-50. View Abstract
130. In vitro enhancement of erythropoiesis by steel factor in Diamond-Blackfan anemia and treatment of other congenital cytopenias with recombinant interleukin 3/granulocyte-macrophage colony stimulating factor. Stem Cells. 1993 Jul; 11 Suppl 2:113-22. View Abstract
131. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol. 1993 Jun; 11(6):1085-91. View Abstract
132. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood. 1993 Apr 01; 81(7):1691-8. View Abstract
133. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991 Oct 15; 78(8):2139-49. View Abstract
134. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990 Oct; 8(10):1707-14. View Abstract
135. A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood. 1990 Sep 15; 76(6):1077-82. View Abstract
136. Renal insufficiency after total body irradiation for pediatric bone marrow transplantation. Radiother Oncol. 1990; 18 Suppl 1:139-42. View Abstract
137. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Prog Clin Biol Res. 1990; 333:207-15. View Abstract
138. Bone marrow transplantation for children with myelodysplastic syndromes. Blood. 1989 Feb; 73(2):619-22. View Abstract
139. Vascular endothelial cells enhance T cell responses by markedly augmenting IL-2 concentrations. Cell Immunol. 1989 Jan; 118(1):166-77. View Abstract
140. Cytoplasmic transfer between endothelium and lymphocytes: quantitation by flow cytometry. Am J Pathol. 1988 Sep; 132(3):406-9. View Abstract
141. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood. 1988 Aug; 72(2):451-5. View Abstract
142. Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):99-104. View Abstract
143. Bone marrow transplantation for constitutional pure red cell aplasia. Blood. 1988 Jan; 71(1):226-9. View Abstract
144. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986 Nov; 68(5):1114-8. View Abstract
145. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol. 1986 Apr; 123(1):16-24. View Abstract
146. Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation. 1985 Jun; 39(6):671-3. View Abstract
Show All Publications Show Fewer Publications